Timing of Bone Marrow Cell Delivery Has Minimal Effects on Cell Viability and Cardiac Recovery After Myocardial Infarction

Background—Despite ongoing clinical trials, the optimal time for delivery of bone marrow mononuclear cells (BMCs) after myocardial infarction is unclear. We compared the viability and effects of transplanted BMCs on cardiac function in the acute and subacute inflammatory phases of myocardial infarction. Methods and Results—The time course of acute inflammatory cell infiltration was quantified by FACS analysis of enzymatically digested hearts of FVB mice (n=12) after left anterior descending artery ligation. Mac-1+Gr-1high neutrophil infiltration peaked at day 4. BMCs were harvested from transgenic FVB mice expressing firefly luciferase (Fluc) and green fluorescent protein (GFP). Afterward, 2.5×106 BMCs were injected into the left ventricle of wild-type FVB mice either immediately (acute BMC) or 7 days (subacute BMC) after myocardial infarction, or after a sham procedure (n=8 per group). In vivo bioluminescence imaging showed an early signal increase in both BMC groups at day 7, followed by a nonsignificant trend (P=0.203) toward improved BMC survival in the subacute BMC group that persisted until the bioluminescence imaging signal reached background levels after 42 days. Compared with controls (myocardial infarction+saline injection), echocardiography showed a significant preservation of fractional shortening at 4 weeks (acute BMC versus saline; P<0.01) and 6 weeks (both BMC groups versus saline; P<0.05) but no significant differences between the 2 BMC groups. FACS analysis of BMC-injected hearts at day 7 revealed that GFP+ BMCs expressed hematopoietic (CD45, Mac-1, Gr-1), minimal progenitor (Sca-1, c-kit), and no endothelial (CD133, Flk-1) or cardiac (Trop-T) cell markers. Conclusion—Timing of BMC delivery has minimal effects on intramyocardial retention and preservation of cardiac function. In general, there is poor long-term engraftment and BMCs tend to adopt inflammatory cell phenotypes.

[1]  Rutger-Jan Swijnenburg,et al.  Comparison of Different Adult Stem Cell Types for Treatment of Myocardial Ischemia , 2008, Circulation.

[2]  Jeroen J. Bax,et al.  Cell therapy for ischaemic heart disease , 2008, Heart.

[3]  N. Rosenthal,et al.  Interleukin-10 From Transplanted Bone Marrow Mononuclear Cells Contributes to Cardiac Protection After Myocardial Infarction , 2008, Circulation research.

[4]  F. Magrini,et al.  Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction , 2008, Journal of Translational Medicine.

[5]  Joseph C. Wu,et al.  Comparison of Imaging Techniques for Tracking Cardiac Stem Cell Therapy , 2007, Journal of Nuclear Medicine.

[6]  Stefanie Dimmeler,et al.  Cell-Based Therapy of Myocardial Infarction , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Christopher H Contag,et al.  Molecular Imaging of Bone Marrow Mononuclear Cell Homing and Engraftment in Ischemic Myocardium , 2007, Stem cells.

[8]  M. Al-mallah,et al.  Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. , 2007, Archives of internal medicine.

[9]  R. Luo,et al.  Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[10]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[11]  B. Fleischmann,et al.  Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction. , 2006, Journal of molecular and cellular cardiology.

[12]  M. Ashraf,et al.  Bone Marrow Stem Cells Prevent Left Ventricular Remodeling of Ischemic Heart Through Paracrine Signaling , 2006, Circulation research.

[13]  W. Wijns,et al.  Timing of intracoronary bone-marrow-derived stem cell transplantation after ST-elevation myocardial infarction , 2006, Nature Clinical Practice Cardiovascular Medicine.

[14]  H. Vogel,et al.  Embryonic Stem Cell Immunogenicity Increases Upon Differentiation After Transplantation Into Ischemic Myocardium , 2005, Circulation.

[15]  A. Mathur,et al.  Stem cells and repair of the heart , 2004, The Lancet.

[16]  N. Khaper,et al.  Inflammatory cytokines and postmyocardial infarction remodeling. , 2004, Circulation research.

[17]  I. Weissman,et al.  Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium , 2004, Nature.

[18]  Irving L. Weissman,et al.  Shifting foci of hematopoiesis during reconstitution from single stem cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Weisel,et al.  Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury. , 2001, The Annals of thoracic surgery.

[20]  A. Kosaki,et al.  Implantation of Bone Marrow Mononuclear Cells Into Ischemic Myocardium Enhances Collateral Perfusion and Regional Function via Side Supply of Angioblasts, Angiogenic Ligands, and Cytokines , 2001, Circulation.

[21]  David M. Bodine,et al.  Bone marrow cells regenerate infarcted myocardium , 2001, Nature.

[22]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.